Open AccessPharmacoeconomic Considerations Associated with the Use of Intravenous-to-Oral Moxifloxacin for Community-Acquired Pneumonia
Author(s) -
Susan L. Davis,
George Delgado,
Peggy S. McKin
Publication year - 2005
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/428054
Subject(s) - medicine , moxifloxacin , pneumonia , community acquired pneumonia , pharmacist , antibiotics , pharmacy , surgery , family medicine , microbiology and biotechnology , biology
Intravenous-to-oral (iv/po) conversion is one cost-effective approach to the management of community-acquired pneumonia (CAP).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom